MIAMI, Oct. 05, 2023 (GLOBE NEWSWIRE) — Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will present a corporate overview…Read More
Related Posts
Active pharmaceutical ingredients market size to grow by USD 8874 billion from 2022 to 2027…
NEW YORK, April 25, 2023 /PRNewswire/ -- The active pharmaceutical ingredients market size is forecasted to increase by USD 88.74 billion from 2022 to 2027, at a CAGR of 7.24%,…
Pasithea Therapeutics Special Committee Rejects Unsolicited Bid from Lucy Scientific Discovery Inc Pasithea Therapeutics NASDAQKTTA…
PALO ALTO, Calif. and MIAMI, July 20, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. KTTA ("Pasithea" or the "Company"), a biotechnology company focused on the discovery, research, and development of…
Tarsus Appoints Jeff Farrow as Chief Financial Officer and Chief Strategy Officer
IRVINE, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize…
